Dronabinol (THC) Significantly Reduces Frequency and Intensity of PTSD Nightmares — Successful Randomized Clinical Trial in 171 Participants

Dronabinol, a THC-containing pharmaceutical, significantly reduced the frequency and intensity of nightmares in patients with PTSD. In a randomized clinical trial involving 171 participants, the drug produced positive results, supporting its potential as a therapeutic option for PTSD.

For the full article, please visit the original source link below. CannabisInsight curates and summarizes key news from the global cannabis and hemp industry.